Option chain shows key data for Polyrizon's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Polyrizon.

Polyrizon (NASDAQ:PLRZ) Stock, Option Chain

Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Equities

News

Small Cap

Movers

PLRZ

Polyrizon shares rise after disclosing the publication of a national phase patent application for nasal protection and drug delivery technologies.

Why Is Development-Stage Biotech Company Polyrizon Stock Surging Today?

Crude Oil 6- logo

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CRVS

KULR

RNAZ

Crude Oil Gains Over 1%, General Mills Shares Fall

pharmaceutical drug medicine FDA

Polyrizon shares are moving higher after the company announced it secured a manufacturing agreement with Eurofins CDMO Amatsiaquitaine.

What&#39;s Going On With Polyrizon Shares Wednesday?

Polyrizon Ltd

Health Care

Press Releases

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

Management

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Legal

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

CMND

CSE:CMND

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Capstone Holding

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Entero Therapeutics

Genprex

GRI Bio

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Comments

Polyrizon

Polyrizon (PLRZ) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga